sincalide

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-2.162		Moderate	0.72
caco2-efflux	Caco-2 efflux ratio (BA/AB)	3.206		Moderate	0.72
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.089	10^-6 cm/s	Moderate	0.72
dh-clint	Dog hepatocyte intrinsic clearance	2.061	uL/min/10^6 cells	Moderate	0.72
dppb	Dog plasma protein binding (% unbound)	50.060	%	Moderate	0.72
fcs-ppb	Fetal calf serum protein binding (% unbound)	27.500	%	Moderate	0.72
herg	hERG pIC50	4.599	pIC50	Moderate	0.72
hh-clint	Human hepatocyte intrinsic clearance	74.817	uL/min/10^6 cells	Moderate	0.72
hlm-clint	Human liver microsomal intrinsic clearance	7.379	uL/min/mg protein	Moderate	0.72
hppb	Human plasma protein binding (% unbound)	40.840	%	Moderate	0.72
kinase-safety-class	ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70	39
kinase-selectivity-class	AXL,GRK2,PDK4	3
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.706		Moderate	0.72
mh-clint	Mouse hepatocyte intrinsic clearance	117.761		Moderate	0.72
mppb	Mouse plasma protein binding (% unbound)	25.880		Moderate	0.72
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.944		Moderate	0.72
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	15.520	%	Moderate	0.72
rh-clint	Rat hepatocyte intrinsic clearance	140.605	uL/min/10^6 cells	Moderate	0.72
rh-fuinc	Rat hepatocyte fraction unbound in incubation	41.120	%	Moderate	0.72
rppb	Rat plasma protein binding (% unbound)	20.940	%	Moderate	0.72
solubility-dd	Solubility at pH 7.4 in DMSO	729.458	uM	Moderate	0.72

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple use of single-use product	244.51	91.91	28	128	1268	110587875
Therapeutic product effect decreased	141.07	91.91	37	119	244279	110344864

Source	Code	Description
ATC	V04CC03	VARIOUS DIAGNOSTIC AGENTS OTHER DIAGNOSTIC AGENTS Tests for bile duct patency
FDA CS	M0004235	Cholecystokinin
FDA EPC	N0000175798	Cholecystokinin Analog

Disease	Relation	SNOMED_ID
Diagnostic aid	indication	2949005
Diagnostic Test for Pancreas Function	indication
Gastrointestinal obstruction	contraindication	126765001
Pregnancy, function	contraindication	289908002
Gallstone Complications	contraindication

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.68	acidic
pKa2	3.79	acidic
pKa3	12.75	acidic
pKa4	12.79	acidic
pKa5	13.18	acidic
pKa6	13.27	acidic
pKa7	13.67	acidic
pKa8	13.79	acidic
pKa9	8.42	Basic

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

sincalide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.005MG/VIAL	SINCALIDE	MAIA PHARMS INC	N210850	Nov. 22, 2022	RX	POWDER	INTRAVENOUS	11110063	April 20, 2038	DIAGNOSIS OF GALL BLADDER DISORDERS OR OTHER DIAGNOSTIC IMAGING BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
0.005MG/VIAL	SINCALIDE	MAIA PHARMS INC	N210850	Nov. 22, 2022	RX	POWDER	INTRAVENOUS	11110063	April 20, 2038	DIAGNOSIS OF PANCREATIC DISORDERS BY STIMULATING PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS
0.005MG/VIAL	SINCALIDE	MAIA PHARMS INC	N210850	Nov. 22, 2022	RX	POWDER	INTRAVENOUS	11110063	April 20, 2038	DIAGNOSTIC IMAGING BY ACCELERATING THE TRAN IT OFA BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT
0.005MG/VIAL	SINCALIDE	MAIA PHARMS INC	N210850	Nov. 22, 2022	RX	POWDER	INTRAVENOUS	11318100	April 20, 2038	ACCELERATE THE TRANSIT OF A BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT
0.005MG/VIAL	SINCALIDE	MAIA PHARMS INC	N210850	Nov. 22, 2022	RX	POWDER	INTRAVENOUS	11318100	April 20, 2038	STIMULATE GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
0.005MG/VIAL	SINCALIDE	MAIA PHARMS INC	N210850	Nov. 22, 2022	RX	POWDER	INTRAVENOUS	11318100	April 20, 2038	STIMULATE GALLBLADDER CONTRACTION. AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
0.005MG/VIAL	SINCALIDE	MAIA PHARMS INC	N210850	Nov. 22, 2022	RX	POWDER	INTRAVENOUS	11318100	April 20, 2038	STIMULATE PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS
0.005MG/VIAL	SINCALIDE	MAIA PHARMS INC	N210850	Nov. 22, 2022	RX	POWDER	INTRAVENOUS	11737983	April 20, 2038	DIAGNOSIS OF GALL BLADDER DISORDERS BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
0.005MG/VIAL	SINCALIDE	MAIA PHARMS INC	N210850	Nov. 22, 2022	RX	POWDER	INTRAVENOUS	11737983	April 20, 2038	DIAGNOSIS OF PANCREATIC DISORDERS BY STIMULATING PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Cholecystokinin receptor type A	GPCR	P32238	CCKAR_HUMAN	Ki	9.55	CHEMBL
Gastrin/cholecystokinin type B receptor	GPCR	P32239	GASR_HUMAN	Ki	9.55	CHEMBL
Cholecystokinin receptor type A	GPCR		CCKAR_RAT	Ki	10.05	CHEMBL
Gastrin/cholecystokinin type B receptor	GPCR		GASR_RAT	Ki	9.39	CHEMBL
Gastrin/cholecystokinin type B receptor	GPCR		GASR_MOUSE	IC50	9.52	CHEMBL
Cholecystokinin receptor type A	GPCR		CCKAR_CAVPO	Ki	9.55	CHEMBL
Cholecystokinin receptor	GPCR		CCKAR_MOUSE GASR_MOUSE	Ki	9.52	CHEMBL

ID	Source
D05845	KEGG_DRUG
4017721	VUID
N0000146090	NUI
4017721	VANDF
CHEMBL1121	ChEMBL_ID
3617	INN_ID
DB09142	DRUGBANK_ID
M03GIQ7Z6P	UNII
9800	RXNORM
367299	MMSL
5466	MMSL
d03895	MMSL
001215	NDDF
126222003	SNOMEDCT_US
35765001	SNOMEDCT_US
C0037167	UMLSCUI
D012844	MESH_DESCRIPTOR_UI
CHEBI:135946	CHEBI
9833444	PUBCHEM_CID
C410885	MESH_SUPPLEMENTAL_RECORD_UI
M03GIQ7Z6P	INXIGHT DRUGS

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
KINEVAC	HUMAN PRESCRIPTION DRUG LABEL	1	0270-0556	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 ug	INTRAVENOUS	NDA	23 sections
SIncalide	HUMAN PRESCRIPTION DRUG LABEL	1	51808-203	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	3 ug	INTRAVENOUS	Unapproved drug other	8 sections
SINCALIDE	HUMAN PRESCRIPTION DRUG LABEL	1	63323-579	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 ug	INTRAVENOUS	NDA	24 sections
Sincalide	Human Prescription Drug Label	1	70511-131	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 ug	INTRAVENOUS	NDA	24 sections
Sincalide	HUMAN PRESCRIPTION DRUG LABEL	1	72266-248	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	5 ug	INTRAVENOUS	NDA	24 sections